Objective: The aims of the present study were to profile the expression of microRNA29 family (miR-29s) in blood serum from patients with PD vs unaffected controls and to clarify whether the expression of miR-29s correlates with disease severity, duration or L-dopa therapy and whether it is dependent on patient gender and age.

Background: A reliable and easily applicable diagnostic marker for Parkinson’s disease (PD) is unavailable. The roles of miR-29s in Parkinson’s disease (PD) remain unclear.

Methods: Blood serum miR-29s levels in 80 patients with PD and 80 unaffected controls were assessed by reverse transcription-quantitative real-time PCR. The PCR products were confirmed by cloning and sequencing.

Results: Serum miR-29s levels were significantly downregulated in PD patients compared with their unaffected controls. Serum miR-29s levels in female patients with PD were markedly higher than those in male PD patients. Serum miR-29a and miR-29c expression exhibited a trend towards reduction related to the disease severity.

Conclusions: Our work suggests that serum miR-29s, especially miR-29a and miR-29c might be two candidate biomarkers for PD.

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/downregulation-of-blood-serum-microrna-29-family-in-patients-with-parkinsons-disease/